Cargando…
GnRHa protects the ovarian reserve by reducing endoplasmic reticulum stress during cyclophosphamide-based chemotherapy
Chemotherapy-induced ovarian dysfunction is a serious adverse effect in premenopausal patients with cancer. Gonadotrophin-releasing hormone analogs (GnRHa) protect ovarian function, but its molecular mechanisms have not yet been determined. In this study, we attempted to determine the previously unk...
Autores principales: | Li, Xiaolin, Liu, Sixuan, Chen, Xuan, Huang, Run, Ma, Lisi, Weng, Huaiyu, Yu, Yang, Zong, Xiangyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497541/ https://www.ncbi.nlm.nih.gov/pubmed/34620881 http://dx.doi.org/10.1038/s41523-021-00340-7 |
Ejemplares similares
-
Fertility preservation and GnRHa for chemotherapy: debate
por: Blumenfeld, Zeev
Publicado: (2014) -
GnRHa trigger—the story of the ugly duckling
por: Humaidan, Peter, et al.
Publicado: (2023) -
The Luteal Phase after GnRHa Trigger-Understanding
An Enigma
por: Leth-Moller, Kathrine, et al.
Publicado: (2014) -
Treatment of central precocious puberty using low dose GnRH analogs (GnRHa)
por: Jahagirdar, Rahul, et al.
Publicado: (2015) -
A single sample GnRHa stimulation test in the diagnosis of precocious puberty
por: Yazdani, Parvin, et al.
Publicado: (2012)